Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply gap.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/P92tRq6
via IFTTT
No comments:
Post a Comment